검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Pegfilgrastim | Osimertinib | Gemcitabine Hydrochloride | Olaparib |
Overview Company | Roche / Genentech | Amgen | Janssen Research & Development, LLC | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Kosei Hasegawa, MD, PhD |
Overview Modality | ADC | ADC | ADC | ADC | ADC |
Overview Target | FRα | Ovarian Cancer | FRα | FRα | Ovary Cancer |
Overview Indication | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Cancer; Colon Cancer | Carcinoma, Non-Small-Cell Lung | Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma | Carcinoma, Ovarian Epithelial |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_3 |
Overview Status | RECRUITING | RECRUITING | RECRUITING | RECRUITING | DISCONTINUED |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functiona | — | of ProAgio, which includes reducing hypoxia and modulating TME | targeting Vβ6 and Vβ10 T-cell receptor |
MoA Biomarker | CD20 expression | PD-L1-high | — | HER2 expression | biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t |
PK/PD Half-life | 12.2 h | 80 days | 48 h | — | — |
PK/PD Species | Rat, 048) | Cynomolgus monkey, NHP | — | Mouse | Mouse |
PK/PD Animal (cat.) | Rat | Human, NHP | — | Mouse, In vitro | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | Pharmacokinetic | — | pharmacokinetic | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Rat, 048) | Cynomolgus monkey, NHP, Rat | — | Mouse, Rabbit | Mouse, Rat, Hamster |
Toxicology Animal (cat.) | Mouse, Rat, NHP | Rat | — | Mouse | Rat |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Thrombocytopenia: Monitor platelet count ( 5 | Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening pulmonary symptoms ind | hepatotoxic drugs [see Adverse Reactions (6 | Hepatotoxicity, Including Drug-induced liver injury (DILI): Occurred in patients treated wi |
Clinical Primary efficacy | ORR 95% | ORR 56.7% | ORR 76.7% | ORR 50% | ORR 55.1% |
Clinical ORR | 95.0% | 56.7% | 76.7% | 50% | 55.1% |
Clinical PFS | — | 10.1 | — | — | — |
Clinical OS | — | 24.6 | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT00911170 | ClinicalTrials.gov NCT02296125 | ClinicalTrials.gov NCT00388154 | ClinicalTrials.gov NCT04269200 |
Clinical Data Tier / Score | S · 92 | A · 70 | B · 69 | C · 59 | C · 40 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) | 2026년 7월 6일 (8일 전) | 2026년 7월 6일 (8일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Pegfilgrastim | Osimertinib | Gemcitabine Hydrochloride | Olaparib |
Overview Company | Roche / Genentech | Amgen | Janssen Research & Development, LLC | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Kosei Hasegawa, MD, PhD |
Overview Modality | ADC | ADC | ADC | ADC | ADC |
Overview Target | FRα | Ovarian Cancer | FRα | FRα | Ovary Cancer |
Overview Indication | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Cancer; Colon Cancer | Carcinoma, Non-Small-Cell Lung | Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma | Carcinoma, Ovarian Epithelial |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_3 |
Overview Status | RECRUITING | RECRUITING | RECRUITING | RECRUITING | DISCONTINUED |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functiona | — | of ProAgio, which includes reducing hypoxia and modulating TME | targeting Vβ6 and Vβ10 T-cell receptor |
MoA Biomarker | CD20 expression | PD-L1-high | — | HER2 expression | biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t |
PK/PD Half-life | 12.2 h | 80 days | 48 h | — | — |
PK/PD Species | Rat, 048) | Cynomolgus monkey, NHP | — | Mouse | Mouse |
PK/PD Animal (cat.) | Rat | Human, NHP | — | Mouse, In vitro | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | Pharmacokinetic | — | pharmacokinetic | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Rat, 048) | Cynomolgus monkey, NHP, Rat | — | Mouse, Rabbit | Mouse, Rat, Hamster |
Toxicology Animal (cat.) | Mouse, Rat, NHP | Rat | — | Mouse | Rat |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Thrombocytopenia: Monitor platelet count ( 5 | Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening pulmonary symptoms ind | hepatotoxic drugs [see Adverse Reactions (6 | Hepatotoxicity, Including Drug-induced liver injury (DILI): Occurred in patients treated wi |
Clinical Primary efficacy | ORR 95% | ORR 56.7% | ORR 76.7% | ORR 50% | ORR 55.1% |
Clinical ORR | 95.0% | 56.7% | 76.7% | 50% | 55.1% |
Clinical PFS | — | 10.1 | — | — | — |
Clinical OS | — | 24.6 | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT00911170 | ClinicalTrials.gov NCT02296125 | ClinicalTrials.gov NCT00388154 | ClinicalTrials.gov NCT04269200 |
Clinical Data Tier / Score | S · 92 | A · 70 | B · 69 | C · 59 | C · 40 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) | 2026년 7월 6일 (8일 전) | 2026년 7월 6일 (8일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) |
추천 비교
추천 비교